| Accession |
PRJCA010925 |
| Title |
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer. |
| Relevance |
Medical |
| Data types |
Biomarker
|
| Organisms |
Homo sapiens
|
| Description |
This study is an open-label, phase I clinical study to evaluate the efficacy, tolerability and safety of recombinant fully human anti-TIGIT antibody (IBI939) in combination with recombinant fully human anti-programmed cell death receptor 1 (PD-1) antibody (sintilimab) in subjects with advanced lung cancer. The primary endpoints are safety, recommended phase II Dose (RP2D) and objective response rate (ORR) by IRRC per RECIST v1.1. |
| Sample scope |
Multiisolate |
| Release date |
2023-06-06 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Innovent
|
|
NA
|
A Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
|
|
|
| External link |
|
| Submitter |
zhao
nan (1165095416@qq.com)
|
| Organization |
Jilin Cancer Hospital |
| Submission date |
2022-08-01 |
